Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.
作者信息
Dargaud Yesim, Lienhart Anne, Janbain Maissaa, Le Quellec Sandra, Enjolras Nathalie, Negrier Claude
机构信息
Unite d'Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France
EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France.
出版信息
Haematologica. 2018 Apr;103(4):e181-e183. doi: 10.3324/haematol.2017.185330. Epub 2018 Feb 22.
Abstract
摘要
相似文献
1
Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.使用凝血酶生成试验对一名患有血友病且产生抑制剂并接受艾美赛珠单抗预防治疗的患者的突破性出血进行个性化治疗。
Haematologica. 2018 Apr;103(4):e181-e183. doi: 10.3324/haematol.2017.185330. Epub 2018 Feb 22.
2
Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.依库珠单抗治疗伴因子 VIII 抑制物的血友病 A 患者出血事件的治疗：英国血友病临床医生组织抑制剂工作组和执行委员会的临时指导意见。
Haemophilia. 2018 May;24(3):344-347. doi: 10.1111/hae.13495.
3
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.双特异性抗体emicizumab 治疗 A 型血友病：抑制剂患者的突破。
BioDrugs. 2018 Dec;32(6):561-570. doi: 10.1007/s40259-018-0315-0.
4
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.依库珠单抗预防伴抑制物的血友病 A。
N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.
5
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.一项emicizumab 预防治疗伴抑制物的血友病 A 患儿的多中心、开放性 3 期研究。
Blood. 2019 Dec 12;134(24):2127-2138. doi: 10.1182/blood.2019001869.
6
Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors.使用整体检测方法监测伴有抑制物的甲型血友病患者的emicizumab预防性治疗。
Haemophilia. 2019 Mar;25(2):e121-e123. doi: 10.1111/hae.13689. Epub 2019 Feb 12.
7
Emicizumab for hemophilia A without inhibitors.艾美赛珠单抗治疗无抑制剂的血友病 A。
Expert Rev Hematol. 2019 Jul;12(7):515-524. doi: 10.1080/17474086.2019.1624519. Epub 2019 Jun 4.
8
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.人源化双特异性抗体在血友病 A 中模拟因子 VIII 的功能。
N Engl J Med. 2016 May 26;374(21):2044-53. doi: 10.1056/NEJMoa1511769.
9
A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.一种改良的凝血酶生成试验，用于评估在emicizumab（一种针对IXa/X因子的双特异性抗体）存在下的血浆凝血潜力。
Int J Hematol. 2020 Nov;112(5):621-630. doi: 10.1007/s12185-020-02959-x. Epub 2020 Aug 3.
10
Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.接受emicizumab预防出血事件的血友病 A 患者延迟抑制剂开发的经济影响模型。
J Med Econ. 2019 Dec;22(12):1328-1337. doi: 10.1080/13696998.2019.1669614. Epub 2019 Oct 7.
引用本文的文献
1
Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice.接受依美珠单抗预防治疗的患者使用活化凝血酶原复合物浓缩剂：从证据到临床实践
Res Pract Thromb Haemost. 2025 Jun 17;9(4):102926. doi: 10.1016/j.rpth.2025.102926. eCollection 2025 May.
2
Contemporary approaches to treat people with hemophilia: what's new and what's not?当代血友病治疗方法：新在哪里，旧在何处？
Res Pract Thromb Haemost. 2025 Jan 31;9(1):102696. doi: 10.1016/j.rpth.2025.102696. eCollection 2025 Jan.
3
No correlation between thrombin generation and emicizumab levels: implications for monitoring emicizumab therapy.凝血酶生成与艾美赛珠单抗水平之间无相关性：对监测艾美赛珠单抗治疗的意义。
Res Pract Thromb Haemost. 2024 Dec 17;9(1):102658. doi: 10.1016/j.rpth.2024.102658. eCollection 2025 Jan.
4
Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis.血浆源性凝血因子VIII/血管性血友病因子对重度A型血友病患者接受emicizumab预防治疗效果的体外评估
Clin Exp Med. 2024 Dec 21;25(1):14. doi: 10.1007/s10238-024-01528-4.
5
Thrombin Generation Assay to Support Hematologists in the Era of New Hemophilia Therapies.凝血酶生成试验助力血液科医生应对新型血友病疗法时代。
Int J Lab Hematol. 2025 Apr;47(2):212-220. doi: 10.1111/ijlh.14406. Epub 2024 Dec 11.
6
Thrombin generation to evaluate the complex hemostatic balance of hemophilia A plasma containing direct oral anticoagulant and supplemented by factor VIII.通过凝血酶生成来评估含直接口服抗凝剂且补充了凝血因子 VIII 的甲型血友病血浆的复杂止血平衡。
Res Pract Thromb Haemost. 2024 Sep 23;8(7):102576. doi: 10.1016/j.rpth.2024.102576. eCollection 2024 Oct.
7
Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab.emicizumab 增强选择性致血友病 B 因子 IX 变体的促凝活性。
Blood. 2024 Sep 12;144(11):1230-1235. doi: 10.1182/blood.2023021944.
8
Emicizumab: the hemophilia A game-changer.依美德珠单抗：血友病 A 的变革者。
Haematologica. 2024 May 1;109(5):1334-1347. doi: 10.3324/haematol.2022.282099.
9
Thrombin generation, bleeding and hemostasis in humans: Protocol for a scoping review of the literature.在人类中凝血酶生成、出血和止血：文献范围综述的方案。
PLoS One. 2023 Nov 1;18(11):e0293632. doi: 10.1371/journal.pone.0293632. eCollection 2023.
10
Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center.接受艾美赛珠单抗预防治疗的甲型血友病患者的手术管理：来自一个国家血友病治疗中心的数据。
Res Pract Thromb Haemost. 2023 Aug 23;7(6):102178. doi: 10.1016/j.rpth.2023.102178. eCollection 2023 Aug.
本文引用的文献
1
Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?依库珠单抗，一种识别凝血因子 IX 和 X 的双特异性抗体：它与因子 VIII 相比实际情况如何？
Blood. 2017 Dec 7;130(23):2463-2468. doi: 10.1182/blood-2017-08-801662. Epub 2017 Oct 17.
2
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.依库珠单抗预防伴抑制物的血友病 A。
N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.
3
Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH.关于血友病患者凝血酶生成检测的标准化分析前和分析条件的建议：来自国际血栓与止血学会（ISTH）科学标准化委员会（SSC）的通讯
J Thromb Haemost. 2017 Aug;15(8):1704-1707. doi: 10.1111/jth.13743. Epub 2017 Jun 28.
4
A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.一项针对新型VIII因子模拟双特异性抗体ACE910在健康受试者中的首次人体1期研究。
Blood. 2016 Mar 31;127(13):1633-41. doi: 10.1182/blood-2015-06-650226. Epub 2015 Dec 1.
5
Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.凝血酶生成可作为重型 A 型血友病伴高滴度抑制物患者治疗反应的客观参数。
Haemophilia. 2014 Jan;20(1):e7-14. doi: 10.1111/hae.12309.
6
Measurement of factor IX activity in plasma-derived and recombinant concentrates: insights from thrombin generation and activation-based assays.血浆源性和重组浓缩物中因子 IX 活性的测量：来自凝血酶生成和基于激活的检测的见解。
J Thromb Haemost. 2014 Jan;12(1):62-70. doi: 10.1111/jth.12452.
7
Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery.前瞻性评估血栓生成试验在接受选择性手术的伴抑制物血友病患者旁路治疗剂量监测中的应用。
Blood. 2010 Dec 16;116(25):5734-7. doi: 10.1182/blood-2010-06-291906. Epub 2010 Sep 1.
8
Insights from factor IX activation studies with chromogenic assays: implications of disparate product results.凝血因子IX显色法激活研究的见解：不同产物结果的影响
Haemophilia. 2010 Jul;16 Suppl 6:9-12. doi: 10.1111/j.1365-2516.2010.02300.x.
9
The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents.在存在抑制剂旁路试剂的情况下，组织因子浓度对校准自动血栓形成测定法的影响。
Int J Lab Hematol. 2009 Apr;31(2):189-98. doi: 10.1111/j.1751-553X.2007.01022.x. Epub 2008 Jan 9.
10
Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.一名高滴度抑制物的重度甲型血友病患者的大手术：凝血酶生成试验在治疗决策中的应用
Haemophilia. 2005 Sep;11(5):552-8. doi: 10.1111/j.1365-2516.2005.01141.x.
Zotero 插件